Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13397797 | 0.84 | — | — | |
| SCHEMBL2307102 | 0.83 | GPR119 (0.31) | GPR119 | |
| SCHEMBL2578044 | 0.80 | HDAC3 (0.30) | — | |
| SCHEMBL2208836 | 0.75 | ATM (0.39) | GPR119 | |
| SCHEMBL4066527 | 0.71 | HDAC3 (0.34) | GPR119 | |
| SCHEMBL21603000 | 0.70 | NOS3 (0.32) | — | |
| SCHEMBL11955778 | 0.68 | — | — | |
| SCHEMBL2400865 | 0.68 | GAA (0.40) | — | |
| SCHEMBL597938 | 0.57 | — | — | |
| SCHEMBL164230 | 0.56 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349256-B1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2349256-B1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| EP-2349256-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | Janssen Pharmaceutica NV (BE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010045166-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045166-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM6 | GPR119 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.